Mechanisms of chemoresistance in cancer stem cells.
Mechanisms of chemoresistance in cancer stem cells.
复制标题
DOI：
10.1186/2001-1326-2-3
复制
发表时间：
2013-01-17
影响因子：
10.6
通讯作者：
Chow EK
中科院分区：
文献类型：
--
作者：
Abdullah LN;Chow EK
化疗是许多癌症的标准治疗方法之一。虽然化疗通常能够诱导肿瘤细胞死亡并减少肿瘤体积，但许多癌症患者会因治疗失败而复发并最终死亡。近年来，癌症干细胞（CSCs）作为关键的肿瘤起始细胞，也可能在化疗后的复发中发挥不可或缺的作用，引起了人们的极大兴趣。因此，已经在CSC中鉴定了许多化学抗性机制。在这篇综述中，我们描述了一些这些机制，包括ABC转运蛋白的表达，醛脱氢酶（ALDH）的活性，B细胞淋巴瘤2（BCL-2）相关的耐药性，增强的DNA损伤反应和激活的关键信号通路。此外，我们评估了证明克服化学抗性和治疗由CSC驱动的化学抗性癌症的潜在方法的研究。通过了解肿瘤起始细胞（如CSC）如何逃避化疗，将开发出更明智的治疗癌症的方法，并可能改善癌症患者的临床结果。
Chemotherapy is one of the standard methods of treatment in many cancers. While chemotherapy is often capable of inducing cell death in tumors and reducing the tumor bulk, many cancer patients experience recurrence and ultimately death because of treatment failure. In recent years, cancer stem cells (CSCs) have gained intense interest as key tumor-initiating cells that may also play an integral role in recurrence following chemotherapy. As such, a number of mechanisms of chemoresistance have been identified in CSCs. In this review, we describe a number of these mechanisms of chemoresistance including ABC transporter expression, aldehyde dehydrogenase (ALDH) activity, B-cell lymphoma-2 (BCL2) related chemoresistance, enhanced DNA damage response and activation of key signaling pathways. Furthermore, we evaluate studies that demonstrate potential methods for overcoming chemoresistance and treating chemoresistant cancers that are driven by CSCs. By understanding how tumor-initiating cells such as CSCs escape chemotherapy, more informed approaches to treating cancer will develop and may improve clinical outcomes for cancer patients.